이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

KALA BIO 관리

관리 기준 확인 2/4

KALA BIO's CEO는 Mark Iwicki, Sep2015 에 임명되었습니다 의 임기는 8.75 년입니다. 총 연간 보상은 $ 8.34M, 8.5% 로 구성됩니다. 8.5% 급여 및 91.5% 보너스(회사 주식 및 옵션 포함). 는 $ 180.27K 가치에 해당하는 회사 주식의 1.23% 직접 소유합니다. 180.27K. 경영진과 이사회의 평균 재임 기간은 각각 6.1 년과 6.8 년입니다.

주요 정보

Mark Iwicki

최고 경영자

US$8.3m

총 보상

CEO 급여 비율	8.5%
CEO 임기	8.8yrs
CEO 소유권	2.6%
경영진 평균 재임 기간	6.2yrs
이사회 평균 재임 기간	6.8yrs

최근 관리 업데이트

Recent updates

The Kala Pharmaceuticals, Inc. (NASDAQ:KALA) Analysts Have Been Trimming Their Sales Forecasts

Aug 10

Is Kala Pharmaceuticals (NASDAQ:KALA) Using Debt Sensibly?

Jul 07

Is Kala Pharmaceuticals (NASDAQ:KALA) Using Debt Sensibly?

Apr 05

Kala Pharmaceuticals, Inc. (NASDAQ:KALA): When Will It Breakeven?

Mar 08

CEO 보상 분석

Mark Iwicki 의 보수는 KALA BIO 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Mar 31 2024	n/a	n/a	-US$40m
Dec 31 2023	US$8m	US$709k	-US$42m
Sep 30 2023	n/a	n/a	-US$46m
Jun 30 2023	n/a	n/a	-US$9m
Mar 31 2023	n/a	n/a	-US$26m
Dec 31 2022	US$2m	US$682k	-US$45m
Sep 30 2022	n/a	n/a	-US$80m
Jun 30 2022	n/a	n/a	-US$137m
Mar 31 2022	n/a	n/a	-US$145m
Dec 31 2021	US$3m	US$644k	-US$143m
Sep 30 2021	n/a	n/a	-US$126m
Jun 30 2021	n/a	n/a	-US$126m
Mar 31 2021	n/a	n/a	-US$113m
Dec 31 2020	US$5m	US$586k	-US$104m
Sep 30 2020	n/a	n/a	-US$95m
Jun 30 2020	n/a	n/a	-US$90m
Mar 31 2020	n/a	n/a	-US$91m
Dec 31 2019	US$3m	US$564k	-US$94m
Sep 30 2019	n/a	n/a	-US$98m
Jun 30 2019	n/a	n/a	-US$90m
Mar 31 2019	n/a	n/a	-US$81m
Dec 31 2018	US$3m	US$535k	-US$67m
Sep 30 2018	n/a	n/a	-US$53m
Jun 30 2018	n/a	n/a	-US$47m
Mar 31 2018	n/a	n/a	-US$44m
Dec 31 2017	US$2m	US$501k	-US$42m

보상 대 시장: Mark 의 총 보상 ($USD 8.34M )은 US 시장( $USD 683.56K ).

보상과 수익: 회사가 수익성이 없는 동안 Mark 의 보상이 증가했습니다.

CEO

Mark Iwicki (58 yo)

8.8yrs

테뉴어

US$8,342,714

보상

Mr. Mark T. Iwicki has been Director at Q32 Bio Inc since March 2023. Mr. Iwicki previously served as the Chairman of Legacy Q32’s board of directors since 2020. He had been Chairman of Aerovate Therapeuti...

리더십 팀

이름	위치	테뉴어	보상	소유권
Mark Iwicki	Chairman & CEO	8.8yrs	US$8.34m	2.57% $ 494.1k
Todd Bazemore	President & COO	6.7yrs	US$2.94m	0.79% $ 152.7k
R. Brazzell	Head of R&D and Chief Medical Officer	11.4yrs	US$2.92m	0.88% $ 168.4k
Justin Hanes	Founder & Chair of the Scientific Advisory Board	no data	데이터 없음	데이터 없음
Mary Reumuth	CFO & Treasurer	10.4yrs	데이터 없음	0.57% $ 109.5k
Jill Steier	Executive Director of Investor Relations & Corporate Communications	3yrs	데이터 없음	데이터 없음
Vincent Kosewski	Senior VP of Manufacturing & Supply Chain Management	7yrs	데이터 없음	데이터 없음
Darius Kharabi	Chief Business Officer	2.7yrs	데이터 없음	0.79% $ 151.1k
Francis Mah	Chief Medical Advisor	1.3yrs	데이터 없음	데이터 없음
Josiah Craver	Senior VP & Corporate Controller	2.3yrs	데이터 없음	데이터 없음
Carl Rennie	Executive Director of Account Management	6.2yrs	데이터 없음	데이터 없음
Patrick Bedell	Executive Director of Trade & Alternate Channels	6.2yrs	데이터 없음	데이터 없음

6.2yrs

평균 재임 기간

56yo

평균 연령

경험이 풍부한 관리: KALA 의 관리팀은 노련하고 경험 (평균 재직 기간 6.1 년)입니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Mark Iwicki	Chairman & CEO	9.3yrs	US$8.34m	2.57% $ 494.1k
Justin Hanes	Founder & Chair of the Scientific Advisory Board	no data	데이터 없음	데이터 없음
Jonathan Silverstein	Board Observer	8.3yrs	데이터 없음	데이터 없음
Gregory Perry	Independent Director	6.4yrs	US$302.01k	0.084% $ 16.2k
Peter Hutt	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Andrew Koven	Lead Independent Director	6.8yrs	US$402.36k	0.11% $ 20.9k
Mark Blumenkranz	Independent Director	2.7yrs	US$234.09k	0.28% $ 52.9k
Ronald Krall	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Bennett Shapiro	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Colin Gardner	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Charles Myers	Independent Director	2.8yrs	US$236.94k	0.047% $ 9.0k
Howard Rosen	Independent Director & Member of Advisory Board	10.5yrs	US$392.20k	0.11% $ 20.5k

6.8yrs

평균 재임 기간

66yo

평균 연령

경험이 풍부한 이사회: KALA 의 이사회는 경험(평균 재직 기간 6.8 년)으로 간주됩니다.

KALA BIO 관리

관리 기준 확인 2/4

주요 정보

최근 관리 업데이트

Chairman & CEO notifies of intention to sell stock

KALA BIO, Inc., Annual General Meeting, Jun 11, 2024

Kala Pharmaceuticals, Inc., Annual General Meeting, Jun 22, 2023

Kala Pharmaceuticals, Inc. Announces Appointment of Marjan Farid to Its Board of Directors

Kala Pharmaceuticals, Inc., Annual General Meeting, Jun 16, 2022

Insufficient new directors

Recent updates

KALA BIO, Inc. announced that it has received $12.499192 million in funding from Baker Bros. Advisors LP, ADAR1 Capital Management, LLC, SR One Capital Management, LP

KALA BIO, Inc. announced that it expects to receive $12.499192 million in funding from Baker Bros. Advisors LP, ADAR1 Capital Management, LLC, SR One Capital Management, LP

KALA BIO, Inc. announced that it expects to receive $12.499192 million in funding from Baker Bros. Advisors LP, ADAR1 Capital Management, LLC, SR One Capital Management, LP

Chairman & CEO notifies of intention to sell stock

KALA BIO, Inc., Annual General Meeting, Jun 11, 2024

KALA BIO, Inc. announced that it expects to receive $8.599799 million in funding from Baker Bros. Advisors LP

KALA BIO, Inc. announced that it expects to receive $1.999824 million in funding

New minor risk - Share price stability

Price target decreased by 13% to US$26.00

Price target decreased by 9.7% to US$31.00

New major risk - Revenue size

First half 2023 earnings released: US$11.35 loss per share (vs US$41.26 loss in 1H 2022)

Kala Pharmaceuticals, Inc., Annual General Meeting, Jun 22, 2023

First quarter 2023 earnings released: US$6.99 loss per share (vs US$22.37 loss in 1Q 2022)

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Kala Pharmaceuticals, Inc. announced that it has received $30.999475 million in funding from Baker Bros. Advisors LP

Kala Pharmaceuticals, Inc. Announces FDA Acceptance of IND Application for KPI-012 for the Treatment of PCED

Kala Pharmaceuticals Receives Non-Compliance Notice From Nasdaq

Consensus forecasts updated

Kala Pharmaceuticals, Inc. announced that it expects to receive $30.999475 million in funding from Baker Bros. Advisors LP

Price target decreased to US$42.00

Price target decreased to US$90.67

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Kala Pharmaceuticals, Inc. Announces Appointment of Marjan Farid to Its Board of Directors

Kala Pharmaceuticals to execute reverse stock split

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Kala Pharmaceuticals Q2 2022 Earnings Preview

Kala Pharmaceuticals, Inc. to Report Q2, 2022 Results on Aug 11, 2022

Kala Pharmaceuticals Receives Non-Compliance Letter from Nasdaq

Alcon Pharmaceuticals Ltd and Alcon Vision, LLC completed the acquisition of EYSUVIS® and certain assets of Kala Pharmaceuticals, Inc. (NasdaqGS:KALA).

Kala Pharmaceuticals Receives Deficiency Letter from the Listing Qualifications Department of the Nasdaq Stock Market

Alcon Inc. (SWX:ALC) entered into a agreement to acquire EYSUVIS® and certain assets of Kala Pharmaceuticals, Inc. (NasdaqGS:KALA) for $385 million.

Consensus revenue estimates fall by 27%

Alcon Inc. (SWX:ALC) acquired EYSUVIS® from Kala Pharmaceuticals, Inc. (NasdaqGS:KALA) for $60 million.

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Kala Pharmaceuticals, Inc. to Report Q1, 2022 Results on May 16, 2022

Kala Pharmaceuticals to Present Clinical Data for KPI-012, its Mesenchymal Stem Cell Secretome Product, for the Treatment of PCED at the 2022 ARVO Annual Meeting

Kala Pharmaceuticals, Inc., Annual General Meeting, Jun 16, 2022

Price target decreased to US$4.55

Insufficient new directors

Consensus forecasts updated

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Insufficient new directors

Third quarter 2021 earnings released: US$0.43 loss per share (vs US$0.50 loss in 3Q 2020)

Staying Patient With Kala Pharmaceuticals

Consensus revenue estimates fall to US$19.9m

The Kala Pharmaceuticals, Inc. (NASDAQ:KALA) Analysts Have Been Trimming Their Sales Forecasts

Price target decreased to US$16.50

Second quarter 2021 earnings released: US$0.56 loss per share (vs US$0.42 loss in 2Q 2020)

No longer forecast to breakeven

Insufficient new directors

Insufficient new directors

Insufficient new directors

Insufficient new directors

Is Kala Pharmaceuticals (NASDAQ:KALA) Using Debt Sensibly?

Consensus forecasts updated

First quarter 2021 earnings released: US$0.49 loss per share (vs US$0.54 loss in 1Q 2020)

Is Kala Pharmaceuticals (NASDAQ:KALA) Using Debt Sensibly?

Kala Pharmaceuticals Announces Preferred Position for Eysuvis™ on Cigna

Kala Pharmaceuticals, Inc. (NASDAQ:KALA): When Will It Breakeven?

CEO 보상 분석

CEO

테뉴어

보상

리더십 팀

평균 재임 기간

평균 연령

이사회 구성원

평균 재임 기간